GFAP and Alzheimer disease: Plasma Aβ42/40 ratio, p-tau, serum neurofilament light chain (NfL) and glial fibrillary acidic protein (GFAP) are the most advanced BBM developed for the diagnosis and prognosis of AD and to potentially monitor the effects of disease-modifying therapies (DMTs).